Issues with medical reimbursements are expected to hinder growth of the global biopsy devices market. Insurance companies do not allow reimbursements for every biopsy procedure. For instance, in European countries, core needle biopsies are not covered for reimbursements as medical insurance companies believe that these are only investigative techniques and not surgical techniques.